

Study of sodium hyaluronate injections for trapeziometacarpal osteoarthritis

Submission date 23/01/2012	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 22/02/2012	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 14/08/2014	Condition category Musculoskeletal Diseases	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Background and study aims

Hand osteoarthritis (OA) is a common disease, and the trapeziometacarpal joint (TMCJ) is commonly targeted by OA. With respect to the long-term results, Hyaluronic Acid (HA) seems to be the better alternative in the treatment of TMCJ OA, even with a single injection. HA injections were found to be effective in reducing pain and improving fine hand function. The aim of this study was to evaluate the effectiveness of injections of HA for the treatment of pain and disability due to TMCJ OA.

Who can participate?

Patients aged 50 to 80 with symptomatic TMCJ OA treated with Hyaluronic Acid between January 2000 and December 2002.

What does the study involve?

All patients received an injection of Hyaluronic Acid once weekly for three consecutive weeks. Examinations were carried out 1, 3 and 6 months after the first treatment.

What are the possible benefits and risks of participating?

All participants will receive a treatment that may improve pain, radial and palmar abduction, pinch strength, duration of morning stiffness and swelling. There are no known serious risks to participants.

Where is the study run from?

This study has been conducted in the private hospitals Villa Regina, at the rheumatology services, and conducted by Prof. Frizziero as principal investigator.

When is the study starting and how long is it expected to run for?

It is a retrospective study collecting data of patients treated in the period within January 2000 and December 2002.

Who is funding the study?

Hospital Accredited Private Villa Regina [L' Ospedale Privato Accreditato Villa Regina] (Italy).

Who is the main contact?
Dr Nicola Giordan
ngiordan@fidiapharma.it

Contact information

Type(s)
Scientific

Contact name
Prof Luigi Frizziero

Contact details
Via Rubiani, 2
Bologna
Italy
40124
luigi.frizziero@libero.it

Additional identifiers

Protocol serial number
Q03-08-01

Study information

Scientific Title
A retrospective study of intra-articular sodium hyaluronate (MW 500-730 KDa) injections for trapeziometacarpal osteoarthritis

Study objectives
The purpose of this retrospective open-label study was to evaluate the efficacy and tolerability of intra-articular injections of HA for the treatment of pain and disability due to trapeziometacarpal joint osteoarthritis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Local Health Authority of Bologna Ethics Committee for Medical Research, 05/05/2009

Primary study design
Interventional

Study design
Retrospective open-label study

Study type(s)
Treatment

Health condition(s) or problem(s) studied

Trapeziometacarpal osteoarthritis

Interventions

All patients underwent one cycle of three weekly intra-articular (i.a.) injections of 0.8 mL (10 mg /mL) of Hyalgan® (hyaluronan) (MW 500 730 KDa) using a dorsolateral approach after palpating the joint space. Joints were injected with a 22-gauge needle after preparation with 10% povidone iodine and ethyl chloride local spray.

Five visits were scheduled:

Visit one: enrolment and start of therapy

Visit two: during study treatment

Visit three: during study treatment

Visit four: during study treatment (1 months after baseline)

Visit five: during study treatment (3 months after baseline)

Visit six: patient final evaluation (6 months after baseline)

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

At baseline and at each subsequent observation times at 1, 3 and 6 months after the treatment, the efficacy and safety parameters were assessed by the investigator and by patients. The following variables were considered and recorded during the visits:

1. Anamnestic and demographic data (only at baseline)
2. Spontaneous pain on movement
3. Provoked pain on movement
4. Pain during night and day
5. Morning stiffness
6. Physicians global assessment
7. Patients global assessment
8. Palmar and radial abduction
9. Pinch strength
10. Nonsteroidal Antiinflammatory Drugs (NSAIDs) intake
11. Tolerability of the product

Key secondary outcome(s)

Local or systemic safety profile of Hyalgan®

Completion date

31/12/2002

Eligibility**Key inclusion criteria**

1. Patients treated with Hyalgan® in the period within January 2000 and December 2002
2. Patients presenting symptomatic trapeziometacarpal osteoarthritis stated by Kellgren and

Lawrence grade scale

3. Patients with at least 6 months of follow-up

4. Patients aged within 50 and 80 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Arthritic or metabolic pathologies and/or serious trauma

2. Less than 6 months of follow-up

3. Clinically relevant differences in the treatment within enrolled patients

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2002

Locations

Countries of recruitment

Italy

Study participating centre

Via Rubiani, 2

Bologna

Italy

40124

Sponsor information

Organisation

Hospital Accredited Private Villa Regina [L' Ospedale Privato Accreditato Villa Regina] (Italy)

ROR

<https://ror.org/05gwp6g74>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Hospital Accredited Private Villa Regina [L' Ospedale Privato Accreditato Villa Regina] (Italy)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration